SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-151775"
 

Search: onr:"swepub:oai:DiVA.org:liu-151775" > Bortezomib-based th...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Terpos, EvangelosUniv Athens, Greece (author)

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2018-09-05
  • WILEY,2018
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-151775
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-151775URI
  • https://doi.org/10.1111/ejh.13147DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Janssen Global Services; Millennium Pharmaceuticals, Inc.
  • Objective: The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE (R) OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice. Method: Patients scheduled to receive intravenous bortezomib for MM were eligible. The primary objective was to evaluate clinical outcomes, including response, time to response, time to next therapy, treatment-free interval, progression-free survival (PFS), and overall survival (OS). Secondary objectives included safety and healthcare resource utilization. Results: In total, 873 patients with a median of two therapy lines prior to initiating bortezomib were included. The overall response rate (amp;gt;= partial response) was 69%, including 37% complete response/near-complete response. Median time to response was 1.8 months, median time to next therapy was 9.7 months, and median treatment-free interval was 7.9 months. After 22.6 months median follow-up, median PFS was 12.0 months and median OS was 36.1 months. The most common adverse events (AEs) were neuropathy not otherwise specified (19%), diarrhea NOS, and thrombocytopenia (each 17%); 230 (26%) patients discontinued bortezomib due to AEs. Of 689 (79%) patients without baseline peripheral neuropathy (PN), the rate of new-onset any-grade PN increased to 51% (12% grade 3/4) by cycle 8. Overall, 244 (28%) patients were hospitalized, 372 (43%) attended an outpatient visit, and 341 (39%) underwent a diagnostic/therapeutic procedure during bortezomib treatment. Conclusion: These prospective real-world data demonstrate the effectiveness and safety of bortezomib-based therapy for RRMM and confirm high response rates and long OS for this population.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Katodritou, EiriniTheagen Canc Ctr, Greece (author)
  • de la Rubia, JavierUniv Catolica Valencia, Spain (author)
  • Hungria, VaniaTheagen Canc Ctr, Greece; Ctr Estudos Hemoctr Santa Casa Sao Paolo, Brazil (author)
  • Hulin, CyrilleCHU Bordeaux, France (author)
  • Roussou, MariaUniv Athens, Greece (author)
  • Delforge, MichelUniv Hosp Leuven, Belgium (author)
  • Bries, GreetAZ Turnhout, Belgium (author)
  • Stoppa, Anne-MarieInst Paoli Calmettes, France (author)
  • Aagesen, JesperRyhov Cty Hosp, Sweden (author)
  • Sargin, DenizIstanbul Univ, Turkey (author)
  • Belch, AndrewCross Canc Inst, Canada (author)
  • Ahlberg, LuciaRegion Östergötland, Hematologiska kliniken US(Swepub:liu)lucah64 (author)
  • Diels, JorisJanssen Res and Dev, Belgium (author)
  • Olie, Robert A.Janssen Cilag AG, Switzerland (author)
  • Robinson, Don Jr.Janssen Global Serv, NJ USA (author)
  • Spencer, MikeJanssen Cilag UK, England (author)
  • Potamianou, AnnaJanssen Cilag Pharmaceut SACI, Greece (author)
  • van de Velde, HelgiJanssen Res and Dev, Belgium; Millennium Pharmaceut Inc, MA USA (author)
  • Dimopoulos, Meletios A.Univ Athens, Greece (author)
  • Univ Athens, GreeceTheagen Canc Ctr, Greece (creator_code:org_t)

Related titles

  • In:European Journal of Haematology: WILEY101:4, s. 556-5650902-44411600-0609

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view